Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-21-030986
Filing Date
2021-06-04
Accepted
2021-06-04 16:16:16
Documents
7
Effectiveness Date
2021-06-04

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea141958-s8_enlivextherap.htm S-8 74105
2 OPINION OF YIGAL ARNON & CO ea141958ex5-1_enlivextherap.htm EX-5.1 29490
3 CONSENT OF YAREL + PARTNERS. ea141958ex23-2_enlivextherap.htm EX-23.2 2800
4 GRAPHIC ex5-1_001.jpg GRAPHIC 22135
5 GRAPHIC ex5-1_002.jpg GRAPHIC 682
6 GRAPHIC image_001.jpg GRAPHIC 2912
7 GRAPHIC image_002.jpg GRAPHIC 4540
  Complete submission text file 0001213900-21-030986.txt   149876
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-256799 | Film No.: 21996649
SIC: 2834 Pharmaceutical Preparations